Analytical Data
-
Gene name
COL17A1
- Application
-
Alternative Names
180KDA bullous pemphigoid antigen 2Bullous pemphigoid antigen 2
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UMD9
-
Expression Region
1253-1497aa
-
Molecular Weight
28.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
COL17A1, or collagen type XVII alpha 1, is a significant component of the extracellular matrix and plays a crucial role in skin integrity and stability by forming a key part of hemidesmosomes, which anchor the epidermis to the dermis. Mutations in the COL17A1 gene are associated with a rare genetic skin disorder known as epidermolysis bullosa, characterized by extreme skin fragility and blistering. Understanding the molecular mechanisms underlying COL17A1 function is vital for developing targeted therapies. Recombinant COL17A1 protein research has gained attention as it allows for the detailed investigation of its structural and functional properties, providing insights into how mutations disrupt its normal function. Additionally, recombinant COL17A1 can serve as a potential therapeutic agent in regenerative medicine and tissue engineering, offering hope for patients suffering from COL17A1-related conditions. Studies involving COL17A1 recombinant proteins also assist in creating model systems to test new treatment strategies and improve our overall understanding of collagen-based disorders.
